BCCMA: Targeting Gut-Microbiome in Veterans Deployment Related Gastrointestinal and Liver Diseases: Dysbiosis, PTSD, and Epithelial and Immune Biology in Inflammatory Bowel Disease in Veterans
BCCMA:针对退伍军人部署相关胃肠道和肝脏疾病的肠道微生物组:退伍军人炎症性肠病中的生态失调、创伤后应激障碍以及上皮和免疫生物学
基本信息
- 批准号:10586940
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAttenuatedAwardBiologicalBiological AssayBiologyCellsCellular biologyChronic stressClinicalClinical ManagementClinical ResearchColitisCollaborationsColonCrohn&aposs diseaseDataDiagnosisDiseaseEarly DiagnosisEpitheliumFecesFunctional disorderGastroenterologistGastrointestinal DiseasesGene ExpressionGenesGerm-FreeGrantHumanImmuneImmune System DiseasesImmunofluorescence ImmunologicIncidenceInflammatory Bowel DiseasesInflammatory ResponseInterventionIntestinesKnowledgeLinkLiver diseasesMessenger RNAMetagenomicsModalityModelingMolecularMorbidity - disease rateMusOrganoidsOutcomePathogenesisPatientsPersian Gulf SyndromePhysiciansPost-Traumatic Stress DisordersPredispositionPrevalencePreventionProteinsPsychological StressRecording of previous eventsResearchResearch InfrastructureRoleSamplingScientistServicesSourceSpermidineStructureTechniquesTechnologyTestingTissuesUlcerative ColitisVeteransWorkbench to bedsideclinical infrastructurediarrheal diseasedysbiosisexperiencegastrointestinal epitheliumgut bacteriagut inflammationgut microbiomegut-brain axishuman diseasehuman microbiotahumanized mouseimprovedin vivo Modelinflammatory markerintestinal epitheliummetabolomicsmicrobiomemicrobiome alterationmicrobiotamilitary servicemouse modelnovelnovel therapeuticsprogramsresponsestool samplesynergismsystemic autoimmunitysystemic inflammatory responsetranslational goaltranslational impact
项目摘要
This Merit Review Project is part of a Collaborative Merit Review Award (CMA), in response to an RFA seeking
collaborative projects related to military service exposures and post-traumatic stress disorder (PTSD). Here in
CMA2 we focus on the gut microbiome, PTSD, and host features specific to inflammatory bowel disease (IBD)
in Veterans. Our overall CMA has 5 projects based on the concept that while emerging evidence supports the
importance of the gut microbiome in human diseases, there are no systematic studies focusing on the role of the
gut microbiome in deployment-related GI and liver diseases in Veterans. Our overall CMA application, based on
the Roadmap developed by our group, proposes to address this knowledge gap. The questions to be addressed
include the novel role of the gut microbiome and chronic stress in mechanisms underlying the higher incidence
of diarrheal diseases, IBD, and liver diseases in Veterans. A highly collaborative group of high-impact
translational projects (3 CSRD & 2 BLRD) will address: CMA1- the role of Gulf War Illness (GWI) and PTSD gut
microbiome in susceptibility to diarrheal diseases; CMA2 (this project)- the role of PTSD in increased incidence
of IBD/gut inflammation; CMA3- the role of PTSD microbiome in gut-barrier structure and function; CMA4- the
role of PTSD and microbiome in liver disease; and CMA5- functional metagenomics in GWl-related gut
dysfunctions. The CMA approach is critical as the PIs will collaborate on shared sources of: a) gut microbiome
from Veterans; b) metagenomics, metabolomics, and gene expression data; and c) state of the art mouse models
and organoid technologies. This CMA2 proposal considers the following concepts. IBD is increasing in the USA
and in the VA, and causes morbidity in VA patients. Psychological stress, especially PTSD has been implicated
in IBD. PTSD is linked to systemic inflammation and autoimmunity, but specific effects on the gut are unknown.
An altered microbiome (dysbiosis) is strongly associated with IBD. Deployment related PTSD in Veterans may
be related to dysbiosis, which has been linked to an altered gut-brain axis. More work is needed to determine
biological links between PTSD and IBD, which we will study in VA patients. The PI is a gastroenterologist at the
VATVHS, and he and his VA GI colleagues can obtain clinical samples for this project, based on our VINCI
analysis of the high number of IBD patients at the VATVHS who also have PTSD. Our hypothesis is that PTSD
predisposes to and exacerbates IBD in Veterans due to a dysbiotic microbiome, and gut epithelial and
immune dysfunction. The Specific Aims are: 1) To test the hypothesis that the dysbiotic gut microbiome in
PTSD contributes to IBD pathogenesis in Veterans. We will study the gut microbiome and its function in stool
samples and colon tissues. This will be related to deployment history and PTSD assessments. We will utilize: A)
metagenomics; and B) metabolomics. The translational goal is to develop strategies to manipulate the
microbiome to attenuate PTSD and IBD. 2) To test the hypothesis that PTSD dysregulates intestinal epithelial
and immune cell biology and contributes to IBD pathogenesis. We will quantify markers of inflammation
established in our Lab at the level of A) mRNA by qPCR; and B) protein, using standard and multiplex
immunofluorescence, and Luminex assays. We will conduct C) metabolomics and spermidine studies, based on
data from our Lab. The Translational goal is to develop new strategies for diagnosis, prevention, and treatment
of IBD in Veterans. 3) To test the hypothesis that human organoids and human microbiota-associated (HMA)
mice can be used to validate the causal role of specific microbiome constituents and cellular dysfunction in PTSD
and IBD in Veterans. We will use: A) patient-derived organoids from control and IBD patients ± PTSD to establish
microbiome constituents and metabolites causing inflammatory responses; and B) germ-free mice humanized
with VA patient microbiota studied in colitis models. The Translational goal is to develop a bench to bedside
pipeline to guide clinical management of IBD ± PTSD. Together, these studies are expected to improve
understanding of IBD and the interaction with PTSD in Veterans and yield new interventions for VA patients.
该绩效评估项目是协同绩效评估奖(CMA)的一部分,是对RFA寻求的回应
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Keith T. Wilson其他文献
Mo1146 - <em>Helicobacter Pylori</em> Genetic Ancestry in Central America is Consistent with Disrupted Co-Evolution, with Implications for Gastric Cancer Risk
- DOI:
10.1016/s0016-5085(17)32349-1 - 发表时间:
2017-04-01 - 期刊:
- 影响因子:
- 作者:
Gloria Tavera;Ricardo L. Dominguez;Jacquelaine Bartlett;Barbara G. Schneider;Charlotte Buehler Cherry;Dawn Israel;Judith Romero-Gallo;Robertino M. Mera;M. Blanca Piazuelo;Richard M. Peek;Keith T. Wilson;Scott Williams;Douglas Morgan - 通讯作者:
Douglas Morgan
Cyclosporin a (CsA) induces enhanced leukocyte binding by human intestinal microvascular endothelial cells (HIMEC): A mechanism for therapeutic failure in long term IBD therapy?
- DOI:
10.1016/s0016-5085(00)85346-9 - 发表时间:
2000-04-01 - 期刊:
- 影响因子:
- 作者:
Parvaneh Rafiee;Christopher P. Johnson;Pamela J. Fisher;Thomas H. Lamirand;Mona S. Li;Keith T. Wilson;David G. Binion - 通讯作者:
David G. Binion
1145 EVALUATION OF THE SAFETY AND EFFICACY OF EFLORNITHINE (DIFLUOROMETHYLORNITHINE, DFMO) IN PATIENTS WITH GASTRIC PREMALIGNANT CONDITIONS IN THE HIGH INCIDENCE AREAS OF LATIN AMERICA
- DOI:
10.1016/s0016-5085(24)01098-9 - 发表时间:
2024-05-18 - 期刊:
- 影响因子:
- 作者:
Douglas R. Morgan;Ricardo L. Dominguez;Dalton A. Norwood;Eleazar E. Montalvan-Sanchez;Maria B. Piazuelo;Jessica Hernandez-Marrero;Maria Gonzalez-Pons;Elizabeth Bruckheimer;Mark Beasley;Marcia R. Cruz-Correa;Keith T. Wilson - 通讯作者:
Keith T. Wilson
125 - Geospatial Analyses Identify a Clustering of Diffuse Gastric Cancers and Related Risk Exposures in Central America
- DOI:
10.1016/s0016-5085(17)30481-x - 发表时间:
2017-04-01 - 期刊:
- 影响因子:
- 作者:
Charlotte Buehler Cherry;Veronica Escamilla;Ricardo L. Dominguez;Barbara G. Schneider;Margaret L. Gulley;Gloria Tavera;Scott Williams;Dawn Israel;M. Blanca Piazuelo;Keith T. Wilson;Richard M. Peek;Michael Emch;Douglas Morgan - 通讯作者:
Douglas Morgan
1077 - <em>Helicobacter Pylori Cag</em><sup>+</sup> Strains Induce Alterations in the <em>In Vivo</em> Epithelial Proteome that are Associated with Progression of Gastric Carcinogenesis
- DOI:
10.1016/s0016-5085(18)31092-8 - 发表时间:
2018-05-01 - 期刊:
- 影响因子:
- 作者:
Jennifer M. Noto;Kristie Lindsey-Rose;Amanda Hachey;Alberto G. Delgado;Judith Romero-Gallo;Barbara G. Schneider;Timothy Cover;Keith T. Wilson;Juan Carlos Roa;M. Blanca Piazuelo;Richard M. Peek - 通讯作者:
Richard M. Peek
Keith T. Wilson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Keith T. Wilson', 18)}}的其他基金
Spermidine as a New Therapy for Colitis and Chemopreventive for Colitis-associated Carcinogenesis
亚精胺作为结肠炎的新疗法和结肠炎相关癌的化学预防
- 批准号:
10379376 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Spermidine as a New Therapy for Colitis and Chemopreventive for Colitis-associated Carcinogenesis
亚精胺作为结肠炎的新疗法和结肠炎相关癌的化学预防
- 批准号:
10180436 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Spermidine as a New Therapy for Colitis and Chemopreventive for Colitis-associated Carcinogenesis
亚精胺作为结肠炎的新疗法和结肠炎相关癌的化学预防
- 批准号:
10579252 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Dysregulated Polyamine Metabolism in H. pylori-associated Gastric Inflammation and Disease Progression
幽门螺杆菌相关胃炎症和疾病进展中多胺代谢失调
- 批准号:
10196972 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Dysregulated Polyamine Metabolism in H. pylori-associated Gastric Inflammation and Disease Progression
幽门螺杆菌相关胃炎症和疾病进展中多胺代谢失调
- 批准号:
10620757 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Dysregulated Polyamine Metabolism in H. pylori-associated Gastric Inflammation and Disease Progression
幽门螺杆菌相关胃炎症和疾病进展中多胺代谢失调
- 批准号:
10572035 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Immunomodulatory effects of arginine supplementation in colitis and colon cancer
补充精氨酸对结肠炎和结肠癌的免疫调节作用
- 批准号:
9300834 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Immunomodulatory effects of arginine supplementation in colitis and colon cancer
补充精氨酸对结肠炎和结肠癌的免疫调节作用
- 批准号:
8857372 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Immunomodulatory effects of arginine supplementation in colitis and colon cancer
补充精氨酸对结肠炎和结肠癌的免疫调节作用
- 批准号:
8690770 - 财政年份:2013
- 资助金额:
-- - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Idea to Innovation














{{item.name}}会员




